BMS
PTCT icon

Brummer Multi-Strategy’s PTC Therapeutics PTCT Stock Holding History

Brummer Multi-Strategy’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,142
Closed -$1.17M – 13
2025
Q3 		$1.17M Buy
+19,142
New +$997K 21.4% 2

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Brummer Multi-Strategy's PTCT Position: Q4 2025 in Review

Brummer Multi-Strategy sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 19,142 shares — an estimated $1.17M sold.

Brummer Multi-Strategy first reported a position in PTCT in Q3 2025 and held it in 1 quarter. The position peaked at $1.17M in Q3 2025. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • Brummer Multi-Strategy reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brummer Multi-Strategy sold 19,142 PTC Therapeutics shares in Q4 2025, an estimated $1.17M.
  • Brummer Multi-Strategy first reported a position in PTC Therapeutics in Q3 2025 and held it in 1 quarter.
  • Brummer Multi-Strategy's PTC Therapeutics position peaked at $1.17M in Q3 2025.
  • 353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Brummer Multi-Strategy's 13F filing for Q4 2025, filed 4 Feb 2026.